VID 19 vaccine is likely to protect against the more infectious variant of the virus, which was discovered in Britain, according to results of further lab tests released on Wednesday.

The encouraging results from an analysis of blood of participants in trials are based on more extensive analysis than those released by the drugmaker last week.

In those tests, Pfizer said a similar lab studies showed the vaccine was effective against one key mutation that's found in both of the highly transmissible new variants spreading rapidly across Britain and South Africa.

The latest study, which was posted online but is yet to be peer reviewed, was conducted on a synthetic virus with 10 mutations that a characteristic of the variant known as B 117 identified in Britain.

Among the 11 authors of the study are the co founders of biotech.

It provides further hope as record numbers of daily deaths from covert 19 a reported in Britain, which is believed to be driven by the more transmissible variant.